Seaport Therapeutics Cash Flow Statement
NASDAQ: SPTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Seaport Therapeutics has no annual cash flow statement on file yet, so quarterly figures are shown instead.
Seaport Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Seaport Therapeutics generated -$26.1 million of operating cash flow and spent $0 on capital expenditures. That left free cash flow of -$26.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
Seaport Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Net Income | -62.60M | -25.41M | -15.08M | -13.13M |
| Net Income growth (YoY) | — | — | — | — |
| Depreciation & Amortization | 26.00K | 26.00K | 41.00K | 36.00K |
| Stock-Based Compensation | 36.86M | 2.57M | 1.76M | 1.62M |
| Change in Working Capital | 910.00K | 2.78M | -601.00K | -2.00M |
| Operating Cash Flow | -26.14M | -20.17M | -15.32M | -20.20M |
| Capital Expenditures | 0 | 0 | -269.00K | -54.00K |
| Investing Cash Flow | -203.50M | 27.85M | -1.44M | -225.55M |
| Financing Cash Flow | 240.93M | -783.00K | 0 | 0 |
| Net Change in Cash | 11.31M | 6.87M | -16.77M | -245.76M |
| Free Cash Flow | -26.14M | -20.17M | -15.59M | -20.26M |
This table shows 4 quarterly periods of Seaport Therapeutics's cash flow statement, from Q2 2026 back to Q? 2025, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SPTX's reporting calendar. What is a cash flow statement?